166 related articles for article (PubMed ID: 12540867)
21. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency.
Hacein-Bey-Abina S; von Kalle C; Schmidt M; Le Deist F; Wulffraat N; McIntyre E; Radford I; Villeval JL; Fraser CC; Cavazzana-Calvo M; Fischer A
N Engl J Med; 2003 Jan; 348(3):255-6. PubMed ID: 12529469
[No Abstract] [Full Text] [Related]
22. Success for gene therapy: render unto Caesar that which is Caesar's.
Qiao J; Diaz RM; Vile RG
Genome Biol; 2004; 5(8):237. PubMed ID: 15287968
[TBL] [Abstract][Full Text] [Related]
23. The future of gene therapy.
Cavazzana-Calvo M; Thrasher A; Mavilio F
Nature; 2004 Feb; 427(6977):779-81. PubMed ID: 14985734
[No Abstract] [Full Text] [Related]
24. Gene therapy: X-SCID transgene leukaemogenicity.
Thrasher AJ; Gaspar HB; Baum C; Modlich U; Schambach A; Candotti F; Otsu M; Sorrentino B; Scobie L; Cameron E; Blyth K; Neil J; Abina SH; Cavazzana-Calvo M; Fischer A
Nature; 2006 Sep; 443(7109):E5-6; discussion E6-7. PubMed ID: 16988659
[TBL] [Abstract][Full Text] [Related]
25. Safety panel backs principle of gene-therapy trials.
Check E
Nature; 2002 Dec; 420(6916):595. PubMed ID: 12478252
[No Abstract] [Full Text] [Related]
26. Gene therapy put on hold as third child develops cancer.
Check E
Nature; 2005 Feb; 433(7026):561. PubMed ID: 15703711
[No Abstract] [Full Text] [Related]
27. Bubble babies and bathwater.
Nat Biotechnol; 2002 Nov; 20(11):1063. PubMed ID: 12410236
[No Abstract] [Full Text] [Related]
28. Genes can come true.
Phillips H
New Sci; 2002 Nov; 176(2371):30-3. PubMed ID: 12731520
[No Abstract] [Full Text] [Related]
29. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1.
Hacein-Bey-Abina S; Von Kalle C; Schmidt M; McCormack MP; Wulffraat N; Leboulch P; Lim A; Osborne CS; Pawliuk R; Morillon E; Sorensen R; Forster A; Fraser P; Cohen JI; de Saint Basile G; Alexander I; Wintergerst U; Frebourg T; Aurias A; Stoppa-Lyonnet D; Romana S; Radford-Weiss I; Gross F; Valensi F; Delabesse E; Macintyre E; Sigaux F; Soulier J; Leiva LE; Wissler M; Prinz C; Rabbitts TH; Le Deist F; Fischer A; Cavazzana-Calvo M
Science; 2003 Oct; 302(5644):415-9. PubMed ID: 14564000
[TBL] [Abstract][Full Text] [Related]
30. Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency.
McCormack MP; Rabbitts TH
N Engl J Med; 2004 Feb; 350(9):913-22. PubMed ID: 14985489
[No Abstract] [Full Text] [Related]
31. Gene-therapy trials to restart following cancer risk review.
Check E
Nature; 2005 Mar; 434(7030):127. PubMed ID: 15758959
[No Abstract] [Full Text] [Related]
32. [Hematopoietic malignancies and gene therapy].
Ozawa K
Gan To Kagaku Ryoho; 2003 Apr; 30(4):478-82. PubMed ID: 12722677
[TBL] [Abstract][Full Text] [Related]
33. Gene therapy rising?
Hoag H
Nature; 2005 May; 435(7041):530-1. PubMed ID: 15917820
[No Abstract] [Full Text] [Related]
34. Fragile sites are preferential targets for integrations of MLV vectors in gene therapy.
Bester AC; Schwartz M; Schmidt M; Garrigue A; Hacein-Bey-Abina S; Cavazzana-Calvo M; Ben-Porat N; Von Kalle C; Fischer A; Kerem B
Gene Ther; 2006 Jul; 13(13):1057-9. PubMed ID: 16511518
[TBL] [Abstract][Full Text] [Related]
35. Progress toward the genetic treatment of the beta-thalassemias.
Sadelain M; Lisowski L; Samakoglu S; Rivella S; May C; Riviere I
Ann N Y Acad Sci; 2005; 1054():78-91. PubMed ID: 16339654
[TBL] [Abstract][Full Text] [Related]
36. Harmful potential of viral vectors fuels doubts over gene therapy.
Check E
Nature; 2003 Jun; 423(6940):573-4. PubMed ID: 12789298
[No Abstract] [Full Text] [Related]
37. SCID trials to remain on the 'bubble'.
Mandavilli A
Nat Med; 2003 Mar; 9(3):251. PubMed ID: 12612562
[No Abstract] [Full Text] [Related]
38. Gene therapy. What to do when clear success comes with an unclear risk?
Marshall E
Science; 2002 Oct; 298(5593):510-1. PubMed ID: 12386304
[No Abstract] [Full Text] [Related]
39. Genotoxicity of retroviral integration in hematopoietic cells.
Nienhuis AW; Dunbar CE; Sorrentino BP
Mol Ther; 2006 Jun; 13(6):1031-49. PubMed ID: 16624621
[TBL] [Abstract][Full Text] [Related]
40. The leukemogenic risk of integrating retroviral vectors in hematopoietic stem cell gene therapy applications.
Kang EM; Tisdale JF
Curr Hematol Rep; 2004 Jul; 3(4):274-81. PubMed ID: 15217557
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
